This webcast and teleconference is designed to provide a comprehensive review of the mechanistic rationale and up-to-date clinical evidence supporting the use of novel targeted, immunotherapeutic, and antibody-based strategies in gynecologic cancers, including endometrial and cervical cancer, as well as offer expert strategies to leverage clinical trial enrollment for the optimal integration of emerging therapeutic options. The expert panel will also tackle case-based questions on the real-world applications of modern diagnostic assessment and effective, personalized treatment integration strategies, as well as the management of unique adverse events associated with novel immunotherapy and targeted therapeutic options in patients with gynecologic cancers.

• Welcome and Introduction
• Challenging the Status Quo in Endometrial Cancer With Immunotherapy and Targeted Options for Care
• Panel Discussion: Case-based Examples of Innovative Therapies for Endometrial Cancer
• Where Newer Therapeutic Options Fit in Cervical Cancer: Navigating the Way Past Chemotherapy
• Panel Discussion: Case-based Examples of Emerging Advances for Cervical Cancer Treatment
• Conclusions and Q&A Session
• Adjourn

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of gynecologic cancers.

Upon completion of this activity, participants should be better able to:

• Summarize the current treatment role of novel therapeutics, including in conjunction with modern molecular diagnostic testing, in gynecologic cancers
• Describe updated evidence on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and combination therapies, in different patient populations with gynecologic cancers
• Integrate approved and emerging options in the management of endometrial and cervical cancer, including in the context of clinical trials, based on disease characteristics and latest recommendations
• Discuss the spectrum of unique safety considerations with novel targeted, antibody-based, and immunotherapy regimens in patients with gynecologic cancers

This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck & Co., Inc.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Linda R. Duska, MD, MPH

University of Virginia School of Medicine

Charlottesville, Virginia

Charles A. Leath, III, MD, MSPH

The University of Alabama at Birmingham

Birmingham, Alabama

Shannon N. Westin, MD, MPH

The University of Texas MD Anderson Cancer Center

Houston, Texas

The Medical Learning Institute, Inc. (MLI) requires faculty, planners, staff, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they, and their spouse/life partners, may have as related to the content of this activity. These disclosures will be provided to learners prior to the start of the activity. All identified COI are thoroughly vetted and resolved according to MLI policy. MLI is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

*Please note that if you are requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number & DOB (MM/DD). A score of 70% or higher is needed to obtain MOC credit.

Copyright © 2000-2020, PeerView